Patient-Centred Drug Delivery, 7.5 credits

Academic year 2022/2023

  • Autumn 2022, 100%, Campus

    Start date: 29 September 2022

    End date: 30 October 2022

    Application deadline: 19 April 2022

    Application code: UU-39004 Application

    Language of instruction: English

    Location: Uppsala

    Selection: Higher education credits in science and engineering (maximum 240 credits)

    Registration: 22 September 2022 – 29 September 2022

Entry requirements: For students from the:

Master's of Science Programme in Pharmacy the student should have at least 150 credits in the programme, and passed the programme course(s) in pharmaceutics and pharmacokinetics.

Master's Programmes in Drug Discovery and Development and Pharmaceutical Modelling the student should have passed the course in Molecular Biopharmaceutics or equivalent.

For acceptance to freestanding course at least 150 credits are required including at least 15 credits in pharmaceutics and pharmacokinetics. Knowledge in English equivalent to what is required for basic eligibility to Swedish higher education.


If you are not a citizen of a European Union (EU) or European Economic Area (EEA) country, or Switzerland, you are required to pay application or tuition fees. Formal exchange students will be exempted from tuition fees, as well as the application fee. Read more about fees.

Application fee: SEK 900

Tuition fee, first semester: SEK 18,125

Tuition fee, total: SEK 18,125

About the course

The course gives an in-depth understanding of different types of controlled, targeted and selective drug delivery. This includes diffusion of drugs from matrix systems, hydrogels as well as responsive and particle-based drug delivery systems and how these are applied to specific locations in the body as well as to the central nervous system, the lymphatic system and the gastrointestinal tract.

It further covers how disease causes physiological, biochemical and cell biological changes and how this creates conditions for targeted and personalised drug therapy. We study how physiologically initiated release of drugs can be used, as well as metabolic and microbial activation. The course will further give an increased understanding of how the uptake of drugs in cells can be stimulated by binding to receptors on specific cells and drug delivery principles that utilise conjugation to ligands such as antibodies.

We will also investigate aspects of personalised dosage forms and theranostic drug delivery systems that combine diagnosis (especially image-guided diagnosis) and therapy, as well as stimuli-responsive systems. This includes drug delivery systems for macromolecules, e.g. proteins and peptides, vaccines, genes and oligonucleotides, and their intracellular release.

Finally, the course will cover novel formulation technologies (e.g. microfluidics), additive manufacturing (3D printing of dosage forms) and continuous manufacturing.

More information


Department of Pharmacy

Biomedicinskt Centrum BMC, Husargatan 3 752 37 Uppsala

Box 580, 751 23 UPPSALA

Per Larsson